Search Results

Displaying Results 26-27 of 27 "'AIV'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.

Sep 12, 2025, 08:00 ET LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq

compliance period to regain compliance with the Bid Price Rule. The specific basis for this determination, as identified by Nasdaq, is Listing Rule 5810(c)(3)(A)(iv), which states that a company is ineligible for any compliance period if it has effected a reverse stock split within the prior one-year period.

More news about: LakeShore Biopharma Co., Ltd.

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.